JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?
about
JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasmsStructural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations.Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratoryBim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.Etiology of thrombocytosis in a general medicine population: analysis of 801 cases with emphasis on infectious causes.The role of Janus kinases in haemopoiesis and haematological malignancy.JAK2 V617F, MPL W515L and JAK2 Exon 12 Mutations in Chinese Patients with Primary MyelofibrosisThe chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age.Erythroid and megakaryocytic transformation.Comparison of JAK2V617F mutation assessment employing different molecular diagnostic techniques.A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.Sensitive detection and quantification of the JAK2V617F allele by real-time PCR blocking wild-type amplification by using a peptide nucleic acid oligonucleotide.The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.Cl-IB-MECA inhibits human erythropoiesis.Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome.JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplainedJAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?
P2860
Q28749690-C392124D-9A25-4130-A1B8-66EBDAFBB05AQ33501856-8DDBBB84-5A84-4C60-B491-4413D856D482Q33555643-A1EFDE68-9846-45F8-A4C1-8DCD840D646CQ33797357-74ED2B5E-96B0-4EED-A554-B378243D878EQ35790260-4BFC872D-3930-4B45-8DE4-281F5C35A798Q36442091-60325810-F5A6-465F-99B7-FBD82718D00CQ36527760-DA8DE571-ECBB-4FAB-BFF0-2C66BCE59C39Q36563107-8A87DB5A-D851-4134-81C0-E277FEE0B834Q36750606-7FEF8A97-0535-46D9-A423-57230067CE39Q36970205-FEE2B413-BCB1-43CB-B93E-0BA1652AE97AQ37284926-3B96AEDF-8F80-45FB-975C-A09AD2904280Q40069992-03BCF2A8-912E-4C30-826E-A9440BDA11AAQ42870221-DBE65853-4504-4345-9234-EA001947E3FDQ45038631-8E2B64CE-056C-432F-8915-769F257FC860Q51031781-48F06B76-55B4-44BF-A461-664FC38CA92EQ54732689-A9B6D508-3736-42D1-B72C-40D22B5097D1Q58289362-33F86712-204F-424D-A286-B242222D732CQ58455742-CF890039-2F4D-4335-BEF2-159E8CD54DB7
P2860
JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?
description
2006 nî lūn-bûn
@nan
2006 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?
@ast
JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?
@en
type
label
JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?
@ast
JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?
@en
prefLabel
JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?
@ast
JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?
@en
P2860
P1433
P1476
JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?
@en
P2093
Maria E Nelson
P2860
P304
P356
10.1080/10428190500301348
P577
2006-02-01T00:00:00Z